TP53 and ovarian cancer: To test this prediction experimentally we imaged cells migrating into a 2-D scratch-wound in the presence or absence of MEK1/2 inhibitors in two different carcinoma cell lines: A2780s, an ovarian cancer cell line where RCP driven α5β1/EGFR trafficking was promoted by inhibition of αvβ3 with cRGDfV; and H1299s, a non-small cell lung cancer cell line in which α5β1/EGFR trafficking was promoted via mutant p53 expression.